Drug intelligence / Profile preview

KUX-1151

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

KUX-1151 is an investigational small molecule drug developed for the oral treatment of gout and hyperuricemia. It acts as a dual inhibitor of xanthine oxidase (XO), which regulates uric acid production, and uric acid transporter 1 (URAT1/SLC22A12), responsible for the reabsorption of uric acid in the kidneys. By inhibiting both targets, KUX-1151 reduces serum uric acid levels through decreased production and increased excretion. The drug was originally developed by Kissei Pharmaceutical and later licensed to Pfizer for further development. Clinical trials reached phase II in Japan but were discontinued before approval[1][2][3][4][5][6].

Other names: rlbn3010rlbn-3010rlbn 3010

Targets

URAT1 (Uric Acid Transporter 1)XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on KUX-1151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KUX-1151.

Explore the full profile